SEC Filing Summary: Venaxis, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Venaxis, Inc. (formerly AspenBio Pharma, Inc.) on December 19, 2012. The registrant is incorporated in Colorado and is based in Castle Rock, Colorado. The filing reports a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and associated compensation arrangements.
Material Changes
The primary material change reported is the election of Susan A. Evans, Ph.D., FACB, as an independent director. Her term is effective January 1, 2013, expiring at the 2013 Annual Meeting of Shareholders. Dr. Evans has been appointed to the Audit Committee effective January 1, 2013.
Management Commentary and Compensation
Dr. Evans will receive the Company's established non-employee director compensation as described in the 2012 Proxy Statement. Additionally, she will be granted an initial award of non-qualified stock options to purchase 48,000 shares of common stock. The exercise price will equal the closing stock price on the date of grant under the 2002 Stock Incentive Plan. Dr. Evans is currently Vice President, Scientific Affairs at Beckman Coulter (an operating company of Danaher Inc.).
Investor Verification Checklist
- Verify the exact closing stock price on the grant date to determine the exercise price for the 48,000 options.
- Review the 2012 Proxy Statement (filed April 11, 2012) for details on the established non-employee director compensation package.
- Confirm the effective date of Dr. Evans' appointment to the Audit Committee (January 1, 2013).
- Check the Company's 2002 Stock Incentive Plan for remaining share availability and plan terms.